https://www.dyne-tx.com/
Dyne Therapeutics - A biotechnology company developing nucleic acid therapies for rare diseases.
Mar 5, 2026 - Repairing muscle, reclaiming now. Life-transforming therapies for inherited muscle diseases.
dyne therapeuticsbiotechnology company
https://markets.businessinsider.com/news/stocks/dyne-therapeutics-announces-fda-btd-to-dyne-251-1034980258
Dyne Therapeutics announces FDA BTD to DYNE-251 | Markets Insider
Dyne Therapeutics (DYN) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to DYNE-25...
dyne therapeuticsannouncesfdabtdmarkets
https://markets.businessinsider.com/news/stocks/dyne-therapeutics-ceo-buys-911k-in-common-stock-1034900793
Dyne Therapeutics CEO buys $911K in common stock | Markets Insider
In a regulatory filing, Dyne Therapeutics (DYN) disclosed that its CEO John Cox bought 100K shares of common stock on July 14th in a total trans...
dyne therapeuticsceo buysin commonstock marketsinsider
https://www.globenewswire.com/news-release/2025/03/20/3046734/0/en/Dyne-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4-to-Newly-Appointed-Chief-Financial-Officer.html
Dyne Therapeutics Reports Inducement Grants Under Nasdaq
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming...
dyne therapeuticsreportsinducementgrantsnasdaq
https://markets.businessinsider.com/news/stocks/dyne-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-by-underwriters-of-option-to-purchase-additional-shares-1034868215
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by...
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functiona...